Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Tyler Van Buren
TD

Tyler Van Buren

TD Cowen
Wall Street Analyst
★★★★☆
#837
on 13Foresight · ranked by our own returns
51%
Success Rate
-2.4%
Average Return
56 of 110 calls profitable · +33.0% vs benchmark
S&P 500 (SPY)
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 51% of Tyler Van Buren's ratings turned a profit when each position was held for 1 year — averaging -2.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

175 Buy 32 Hold 0 Sell
Tyler's Stock Coverage 65 ratings · 2026-11-09
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
BHVN
Biohaven Ltd.
 Oct 30, 2026 BUY Buy
+51.3% avg upside
25 analysts
$30.00
94.54% Upside
 -8.3% ·
BBIO
BridgeBio Pharma
 Oct 30, 2026 BUY Strong Buy
+26.0% avg upside
36 analysts
$100.00
33.34% Upside
 +0.4% ·
GILD
Gilead Sciences
 Oct 30, 2026 BUY Strong Buy
-27.3% avg upside
66 analysts
$175.00
2.57% Upside
 +2.2% ·
ARTV
Artiva Biotherapeutics, Inc.
 Oct 27, 2026 HOLD Buy
+394.4% avg upside
8 analysts
 — -2.8% ·
CRSP
Crispr Therapeutics AG
 Oct 21, 2026 HOLD Buy
+45.6% avg upside
41 analysts
$45.00
12.39% Downside
 -1.3% ·
RVMD
Revolution Medicines
 Oct 21, 2026 BUY Strong Buy
+8.2% avg upside
36 analysts
$250.00
30.75% Upside
 +3.1% ·
MRNA
Moderna
 Oct 21, 2026 HOLD Hold
-48.5% avg upside
38 analysts
$90.00
59.48% Downside
 +10.7% ·
REGN
Regeneron
 Oct 21, 2026 BUY Strong Buy
-12.2% avg upside
60 analysts
$980.00
5.67% Upside
 +12.1% ·
ADRX
ADARx Pharmaceuticals
 Oct 20, 2026 BUY Strong Buy
+105.9% avg upside
4 analysts
 — -25.2% ·
ETRA
Electra Therapeutics Inc.
 Oct 13, 2026 BUY Strong Buy
+303.3% avg upside
5 analysts
 — -9.4% ·
KRSA
Korsana Biosciences
 Sep 14, 2026 BUY Strong Buy
+27.8% avg upside
7 analysts
 — -1.8% ·
BRVE
Braveheart Bio, Inc.
 Aug 31, 2026 BUY Strong Buy
+95.4% avg upside
5 analysts
 — -16.1% ·
ORKA
Oruka Therapeutics
 Aug 26, 2026 BUY Strong Buy
+37.2% avg upside
16 analysts
 — +3.4% ·
ALLO
Allogene Therapeutics
 Aug 12, 2026 BUY Strong Buy
+1186.8% avg upside
28 analysts
 — -49.8% ·
CCCC
C4 Therapeutics
 Aug 11, 2026 BUY Strong Buy
+405.9% avg upside
21 analysts
 — -19.9% ·
ODTX
Odyssey Therapeutics, Inc.
 Aug 11, 2026 BUY Strong Buy
+83.0% avg upside
6 analysts
 — -5.5% ·
IMNM
Immunome
 Aug 11, 2026 BUY Strong Buy
+81.9% avg upside
19 analysts
 — -25.4% ·
JBIO
Jade Biosciences
 Aug 10, 2026 BUY Strong Buy
+312.1% avg upside
17 analysts
 — -30.6% ·
OLMA
Olema Pharmaceuticals
 Aug 10, 2026 BUY Strong Buy
+401.3% avg upside
16 analysts
 — -40.8% ·
IOVA
Iovance Biotherapeutics
 Aug 06, 2026 BUY Strong Buy
+83.7% avg upside
26 analysts
$7.00
17.37% Downside
 +33.2% ·
ZNTL
Zentalis Pharmaceuticals
 Aug 06, 2026 BUY Buy
+585.1% avg upside
20 analysts
 — -64.8% ·
OBX
Obsidian Therapeutics
 Aug 06, 2026 BUY Strong Buy
+14.6% avg upside
11 analysts
 — -51.1% ·
RNAC
Cartesian Therapeutics
 Aug 06, 2026 BUY Strong Buy
+378.5% avg upside
19 analysts
 — -22.1% ·
ARQT
Arcutis Biotherapeutics
 Aug 05, 2026 BUY Strong Buy
+29.0% avg upside
15 analysts
$35.00
9.09% Upside
 -6.1% ·
TVTX
Travere Therapeutics
 Aug 04, 2026 BUY Strong Buy
+15.5% avg upside
22 analysts
$75.00
48.78% Upside
 +12.0% ·
SMMT
Summit Therapeutics
 Jul 27, 2026 BUY Strong Buy
+83.4% avg upside
29 analysts
 — +24.6% ·
SYRE
Spyre Therapeutics
 Jun 23, 2026 BUY Strong Buy
+1.0% avg upside
25 analysts
 — +7.0% ·
TYRA
Tyra Bioscience
 May 13, 2026 BUY Strong Buy
+107.4% avg upside
17 analysts
 — -41.6% ·
MAZE
Maze Therapeutics, Inc.
 May 12, 2026 BUY Strong Buy
+102.8% avg upside
14 analysts
 — +26.2% ·
ARVN
Arvinas Holding Company
 May 12, 2026 HOLD Buy
+258.0% avg upside
28 analysts
 — -22.5% ·
CGON
CG Oncology, Inc.
 May 11, 2026 BUY Strong Buy
+33.1% avg upside
17 analysts
 — +9.0% ·
BCAX
Bicara Therapeutics Inc.
 May 11, 2026 BUY Strong Buy
+247.0% avg upside
16 analysts
 — -58.9% ·
AKTS
Aktis Oncology, Inc.
 May 11, 2026 BUY Strong Buy
+104.0% avg upside
12 analysts
 — -13.4% ·
TECX
Tectonic Therapeutic
 May 08, 2026 BUY Strong Buy
+176.5% avg upside
24 analysts
 — -28.8% ·
MBX
MBX Biosciences, Inc.
 May 07, 2026 BUY Strong Buy
+53.5% avg upside
14 analysts
 — +47.4% ·
NAMS
NewAmsterdam Pharma Company
 May 07, 2026 BUY Strong Buy
+136.0% avg upside
19 analysts
 — -45.2% ·
IMCR
Immunocore Holdings
 May 06, 2026 BUY Strong Buy
+109.0% avg upside
22 analysts
$60.00
96.71% Upside
 +0.9% ·
IDYA
IDEAYA Biosciences
 May 05, 2026 BUY Strong Buy
+48.2% avg upside
31 analysts
 — +6.4% ·
EYPT
EyePoint Pharmaceuticals
 Nov 05, 2025 BUY Buy
+3222.9% avg upside
21 analysts
$20.00
5640.63% Upside
 · ·
KROS
Keros Therapeutics
 Nov 05, 2025 HOLD Buy
+116.6% avg upside
21 analysts
 — -30.8% ·
RCKT
Rocket Pharmaceuticals
 Aug 08, 2025 HOLD Buy
+546.4% avg upside
30 analysts
 — +26.2% ·
FATE
Fate Therapeutics
 Nov 08, 2023 HOLD Buy
+482.8% avg upside
31 analysts
 — +3.9% ·
ALGS
Aligos Therapeutics
 Mar 11, 2022 BUY Strong Buy
+860.4% avg upside
11 analysts
$15.00
212.46% Upside
 -49.0% ·
IONS
Ionis Pharmaceuticals
 Oct 01, 2021 HOLD Strong Buy
+74.1% avg upside
44 analysts
 — +31.8% ·
INCY
Incyte
 Oct 01, 2021 HOLD Strong Buy
-5.9% avg upside
49 analysts
 — -2.3% ·
GSK
GlaxoSmithKline
 Oct 01, 2021 HOLD Hold
-14.7% avg upside
20 analysts
 — -19.2% ·
BCRX
BioCryst
 Oct 01, 2021 HOLD Strong Buy
+113.8% avg upside
24 analysts
 — -8.2% ·
APOG
Apogee
 Oct 01, 2021 HOLD Strong Buy
+0.2% avg upside
7 analysts
 — +1.3% ·
SRPT
Sarepta Therapeutics
 Oct 01, 2021 HOLD Buy
+223.8% avg upside
50 analysts
 — +15.1% ·
GOSS
Gossamer Bio
 Oct 01, 2021 HOLD Buy
+1287.3% avg upside
17 analysts
 — · ·
MGTX
Meiragtx Holdings
 Oct 01, 2021 HOLD Strong Buy
+166.7% avg upside
14 analysts
 — -36.8% ·
AMRX
Amneal Pharmaceuticals
 Oct 01, 2021 HOLD Buy
-10.1% avg upside
19 analysts
 — -63.5% ·
OVID
Ovid Therapeutics
 Oct 01, 2021 HOLD Strong Buy
+103.8% avg upside
19 analysts
 — -47.9% ·
CYPH
Cypherpunk Technologies
 Oct 01, 2021 HOLD Buy
+191.2% avg upside
9 analysts
 — · ·
ONC
BeOne Medicines
 Oct 01, 2021 HOLD Strong Buy
-1.2% avg upside
29 analysts
 — -62.2% ·
OCUL
Ocular Therapeutix
 Oct 01, 2021 HOLD Strong Buy
+253.9% avg upside
21 analysts
 — -60.0% ·
KURA
Kura Oncology
 Oct 01, 2021 HOLD Strong Buy
+155.5% avg upside
27 analysts
 — -28.6% ·
PRAX
Praxis Precision Medicines
 Oct 01, 2021 HOLD Strong Buy
+99.2% avg upside
25 analysts
 — -88.2% ·
NRIX
Nurix Therapeutics
 Oct 01, 2021 HOLD Strong Buy
+22.5% avg upside
28 analysts
 — -58.3% ·
NGNE
Neurogene
 Oct 01, 2021 HOLD Strong Buy
+79.5% avg upside
24 analysts
 — -91.2% ·
AGIO
Agios Pharma
 Oct 01, 2021 HOLD Strong Buy
+99.0% avg upside
30 analysts
 — -39.0% ·
PLRX
Pliant Therapeutics
 Oct 01, 2021 HOLD Buy
+2494.6% avg upside
21 analysts
 — +21.0% ·
INVA
Innoviva
 Oct 01, 2021 HOLD Strong Buy
+37.9% avg upside
13 analysts
 — -31.8% ·
GYRE
Gyre Therapeutics
 Oct 01, 2021 HOLD Strong Buy
+354.5% avg upside
15 analysts
 — -53.1% ·
NKTR
Nektar Therapeutics
 Oct 01, 2021 HOLD Strong Buy
+97.1% avg upside
26 analysts
 — -82.6% ·
🔒 60 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Tyler Van Buren — Frequently Asked Questions
How accurate are Tyler Van Buren's stock ratings?
Based on the calls 13Foresight could measure, about 48% of Tyler's ratings were profitable over a one-year hold, with an average return of -2.7% per rating, or +35.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Tyler ranked on 13Foresight?
Tyler Van Buren is currently ranked #837 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Tyler cover?
Tyler most recently has ratings on BHVN, BBIO, GILD, ARTV, CRSP, RVMD, MRNA, REGN, ADRX, ETRA, KRSA, BRVE and 53 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.